Literature DB >> 27784901

Targeting mutant p53 through the mevalonate pathway.

William Freed-Pastor1, Carol Prives2.   

Abstract

It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27784901     DOI： 10.1038/ncb3435

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN： 1465-7392            Impact factor:   28.824


  14 in total

Review 1.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

2.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

3.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

4.  DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

Authors:  Alejandro Parrales; Atul Ranjan; Swathi V Iyer; Subhash Padhye; Scott J Weir; Anuradha Roy; Tomoo Iwakuma
Journal:  Nat Cell Biol       Date:  2016-10-24       Impact factor: 28.824

Review 5.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

Review 6.  Proteasome inhibitor therapy in multiple myeloma.

Authors:  Dharminder Chauhan; Teru Hideshima; Constantine Mitsiades; Paul Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2005-04       Impact factor: 6.261

7.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

8.  Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Authors:  Dawid Walerych; Kamil Lisek; Roberta Sommaggio; Silvano Piazza; Yari Ciani; Emiliano Dalla; Katarzyna Rajkowska; Katarzyna Gaweda-Walerych; Eleonora Ingallina; Claudia Tonelli; Marco J Morelli; Angela Amato; Vincenzo Eterno; Alberto Zambelli; Antonio Rosato; Bruno Amati; Jacek R Wiśniewski; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2016-06-27       Impact factor: 28.824

Review 9.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

10.  Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.

Authors:  Milena Wiech; Maciej B Olszewski; Zuzanna Tracz-Gaszewska; Bartosz Wawrzynow; Maciej Zylicz; Alicja Zylicz
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240
View more
  11 in total

1.  MED28 increases the colony-forming ability of breast cancer cells by stabilizing the ZNF224 protein upon DNA damage.

Authors:  Jin Gu Cho; Key-Hwan Lim; Sang Gyu Park
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

2.  Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma.

Authors:  Nilay Sethi; Osamu Kikuchi; James McFarland; Yanxi Zhang; Max Chung; Nicholas Kafker; Mirazul Islam; Benjamin Lampson; Abhishek Chakraborty; William G Kaelin; Adam J Bass
Journal:  JCI Insight       Date:  2019-08-08

Review 3.  An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer.

Authors:  Candace Miyaki; Launa M Lynch
Journal:  Cureus       Date:  2022-05-30

Review 4.  Pathogenesis and heterogeneity of ovarian cancer.

Authors:  Paul T Kroeger; Ronny Drapkin
Journal:  Curr Opin Obstet Gynecol       Date:  2017-02       Impact factor: 1.927

5.  Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.

Authors:  Elizabeth de Wolf; Marwan Ibrahim Abdullah; Stefanie M Jones; Karen Menezes; Darren M Moss; Falko P Drijfhout; Sarah R Hart; Clare Hoskins; Euan A Stronach; Alan Richardson
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 6.  Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Authors:  Maria Ferraiuolo; Lorena Verduci; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-05-03       Impact factor: 5.923

Review 7.  Altered Mitochondrial Signalling and Metabolism in Cancer.

Authors:  Esita Chattopadhyay; Bidyut Roy
Journal:  Front Oncol       Date:  2017-03-20       Impact factor: 6.244

8.  The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.

Authors:  Anjana Bhardwaj; Harpreet Singh; Celestine Marie Trinidad; Constance T Albarracin; Kelly K Hunt; Isabelle Bedrosian
Journal:  Breast Cancer Res       Date:  2018-12-11       Impact factor: 6.466

Review 9.  Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.

Authors:  Yan Stein; Varda Rotter; Ronit Aloni-Grinstein
Journal:  Int J Mol Sci       Date:  2019-12-08       Impact factor: 5.923

10.  Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients.

Authors:  Yupeng Liu; Jingchen Yan; Feng Wang
Journal:  Oncol Lett       Date:  2018-08-30       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.